Targeting TGF-beta signaling for the treatment of fibrosis

Györfi AH, Matei AE, Distler J (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Matrix Biology Elsevier

Book Volume: 68-69

Pages Range: 8-27

DOI: 10.1016/j.matbio.2017.12.016

Abstract

Transforming growth factor-alpha (TGF-beta) is widely recognized as a core pathway of fibrosis. Inhibition of TGF-beta signaling may thus offer potential for antifibrotic therapies. Long-term inhibition of TGF-beta signaling at the level of its isoforms and receptors can be associated with unacceptable adverse effects. However, TGF-beta regulates a myriad of intracellular signaling cascades to transmit its profibrotic effects and several of those pathways offer potential for pharmacologic intervention. Moreover, the multiple interactions of TGF-beta with other profibrotic pathways also yielded candidates for therapeutic intervention. In this review, we discuss selected targets within the TGF-beta pathway with high translational potential. (C) 2018 Elsevier B.V. All rights reserved.

Authors with CRIS profile

Andrea-Hermina Györfi Department of Medicine 3 – Rheumatology and Immunology Alexandru-Emil Matei Department of Medicine 3 – Rheumatology and Immunology Jörg Distler Professur für Molekulare Mechanismen der Organfibrose

How to cite

APA:

Györfi, A.-H., Matei, A.-E., & Distler, J. (2018). Targeting TGF-beta signaling for the treatment of fibrosis. Matrix Biology, 68-69, 8-27. https://doi.org/10.1016/j.matbio.2017.12.016

MLA:

Györfi, Andrea-Hermina, Alexandru-Emil Matei, and Jörg Distler. "Targeting TGF-beta signaling for the treatment of fibrosis." Matrix Biology 68-69 (2018): 8-27.

BibTeX: Download